MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
470.83
+1.15
+0.24%
Opening 12:10 01/09 EST
OPEN
467.73
PREV CLOSE
469.68
HIGH
475.33
LOW
467.06
VOLUME
299.64K
TURNOVER
--
52 WEEK HIGH
519.68
52 WEEK LOW
362.50
MARKET CAP
119.46B
P/E (TTM)
33.08
1D
5D
1M
3M
1Y
5Y
1D
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
The Motley Fool · 2h ago
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
NASDAQ · 18h ago
Vertex Pharmaceuticals EVP, CO & FO Charles F. Wagner Jr. Reports Disposal of Common Shares
Reuters · 20h ago
Vertex Pharmaceuticals (VRTX) Is Up 6.8% After IgA Nephropathy Outlook Upgrade - Has The Bull Case Changed?
Simply Wall St · 22h ago
$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Benzinga · 1d ago
Vertex Advances Suzetrigine Phase 3 Trial in Diabetic Nerve Pain, Signaling a Broader Growth Story
TipRanks · 1d ago
Andrew Hill Investment Advisors adds GS, TMO, PG, DE exits COST among Q4 moves
Seeking Alpha · 1d ago
Sionna Therapeutics price target raised to $58 from $50 at BTIG
TipRanks · 1d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Webull offers Vertex Pharmaceuticals Inc stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.